PHAT Q2 2024 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M

Gross Profit

$6M81.2% margin

Operating Income

-$77M-1055.4% margin

Net Income

-$91M-1248.6% margin

EPS (Diluted)

$-1.56

QoQ Revenue Growth

+283.1%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$71M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$319M

Total Liabilities

$553M

Stockholders' Equity

-$234M

Cash & Equivalents

$276M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$0	—
Gross Profit	$6M	-$123,000	+4935.8%
Operating Income	-$77M	-$32M	-143.8%
Net Income	-$91M	-$41M	-123.2%